Physician profile
Edward James Tanner
NPI 1013059781
$208,916.77
in general payments reported to CMS, 2019-2025
15 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $628 · 2021: $28K · 2022: $69K · 2023: $96K · 2024: $14K · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Travel and Lodging: $15K · Consulting Fee: $9,565 · Education: $4,100 · Food and Beverage: $2,311 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,911.25 |
| Travel and Lodging | $15,463.03 |
| Consulting Fee | $9,565.00 |
| Education | $4,099.99 |
| Food and Beverage | $2,311.37 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $102.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $65,350.52 | 2019-2024 | Lynparza |
| Eisai INC. | $56,058.86 | 2022-2024 | |
| Immunogen, INC. | $34,485.32 | 2023 | Elahere |
| Merck Sharp & Dohme LLC | $26,095.82 | 2019-2024 | Keytruda |
| Ethicon INC. | $19,191.81 | 2019-2022 | |
| Intuitive Surgical, INC. | $6,130.74 | 2019-2024 | Da Vinci Surgical System |
| Foundation Medicine, INC. | $707.54 | 2021-2023 | |
| Davol INC. | $263.33 | 2019-2024 | Arista Ah Flexitip |
| Seagen INC. | $198.25 | 2023-2025 | |
| Hologic Sales and Service, LLC | $119.99 | 2025 | Acessa Provu System |
| Myovant Sciences INC. | $82.41 | 2021 | |
| Myriad Genetic Laboratories, INC. | $79.76 | 2021 | |
| Clovis Oncology, INC. | $76.25 | 2021 | |
| Abbvie INC. | $48.31 | 2024 | |
| Glaxosmithkline, LLC. | $27.86 | 2023 | Zejula, Jemperli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.